Join the Crohn's Disease - Acute group to help and get support from people like you.
Crohn's Disease - Acute News (Page 2)
Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
FRIDAY, Oct. 18, 2024 – For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published online Oct. 15 in the...
Crohn's, Colitis Care Take Big Financial Toll on Patients
THURSDAY, Oct. 10, 2024 – Inflammatory bowel conditions such as Crohn’s disease and colitis cause intense financial pressure as well as physical distress, a new study shows. More than 40% of people w...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
Televisit Outpatient Care Feasible for Inflammatory Bowel Disease
FRIDAY, Aug. 23, 2024 – Televisit-delivered outpatient care for inflammatory bowel disease (IBD) is not associated with a higher risk for IBD-related hospitalization, according to a study published...
4 Tips to Keeping Your Gut Healthy and Free of IBD
TUESDAY, Aug. 6, 2024 – Almost 2.4 million Americans are thought to suffer from the pain and disability of inflammatory bowel disorder (IBD), a type of autoimmune illness that includes ulcerative...
Study Compares Surgical Techniques for Crohn Disease
THURSDAY, Aug. 1, 2024 – For patients undergoing open or laparoscopic resection of the small bowel or strictureplasty for Crohn disease (CD), small bowel resection is associated with the longest...
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 – For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission...
'Microrobot' Pills Eased IBD in Mice, Paving Way for Human Testing
FRIDAY, June 28, 2024 – A new "microrobot" pill may help tame inflammatory bowel disease (IBD), a new study in mice suggests. The pill significantly reduced IBD symptoms in mice and promoted the...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 – There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD)...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric...
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...
FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Rem...
Further information
Related condition support groups
Related drug support groups
prednisone, metronidazole, Humira, ciprofloxacin, hydrocortisone, betamethasone, cortisone, Stelara, Remicade, view more... prednisolone, dexamethasone, adalimumab, budesonide, ustekinumab, Cimzia